The aim of this study was to investigate the role of polyclonal free light chains (FLCs) of the immunoglobulins as markers of immune activation in the management of psoriatic patients on treatment with biologics. The overall study population included 30 patients affected by mild-to-severe psoriasis with either ongoing biological treatment or without any current systemic therapy and 10 healthy controls. FLCs, which include κ and λ chains, were determined by quantitative nephelometric assay while antinuclear antibodies (ANA) through immunofluorescence. Psoriatic patients showed significant increased levels of κ and λ FLCs compared to healthy controls. Interestingly, κ and λ FLCs values were significantly increased only in psoriatic patients with ongoing biological treatment and in particular in responder subjects. Furthermore, correlation of both κ and λ FLCs with duration of therapy showed significant results. Patients with FLC levels above the normality range and under biological treatment for more than 12 months showed higher odds to be ANA+ respect to patients with FLC levels above the normality range but under biological treatment for less than 12 months. Increased FLCs levels would seem to act as markers of immune reactivation in psoriatic patients on treatment with biologic agents suggesting that the determination of FLCs could have clinical relevance in psoriasis clinical management

ESDR240 - Serum polyclonal free light chains: possible markers of immune activation in psoriasis

50th Annual Meeting of the European Society for Dermatological Research. VIRTUAL MEETING